© Georg Thieme Verlag KG Stuttgart · New York
The Number Needed to Treat for All-Cause Medication Discontinuation in the Treatment of Schizophrenia: Consistency Across World Geographies and Study Designs
16 December 2009 (eFirst)
Introduction: The number needed to treat (NNT) for all-cause medication discontinuation in large, industry-sponsored, non-randomized, observational studies conducted across world geographies was compared with NNTs from CATIE, an 18-month, NIMH-sponsored, randomized study.
Methods: NNTs (with 95% confidence intervals) were calculated using data from 3 large Lilly-sponsored, non-randomized, observational studies (EU-SOHO, IC-SOHO, and US-SCAP, n=20 957). Group differences at medication initiation were adjusted by Cox regression modeling. These NNTs were compared with published NNTs for CATIE (phase 1).
Results: NNTs for olanzapine vs. risperidone and for olanzapine vs. quetiapine were similar across the observational studies and similar to those of CATIE. The NNTs for olanzapine vs. oral typical antipsychotics were similar across the observational studies but demonstrated a somewhat stronger effect size than the NNT reported for olanzapine vs. perphenazine in CATIE.
Discussion: NNTs for all-cause treatment discontinuation (a proxy measure of a medication's effectiveness from patients’ and clinicians’ perspectives) appear to be consistent across study designs (non-interventional, observational vs. RCT), study sponsorship (industry vs. independent), and across world geographies, suggesting that antipsychotics differ in this measure.
- 1 Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998; 317 1309-1312
- 2 Altman DG, Andersen PK. Calculating the number needed to treat for trials where outcome is time to event. BMJ. 1999; 319 1492-1495
- 3 American Psychiatric Association . Practice Guidelines for the Treatment of Patients with Schizophrenia, 2nd edition. Am J Psychiatry. 2004; 161 1-56
- 4 Ascher-Svanum H, Faries DE, Zhu B. et al . Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006; 67 453-460
- 5 Ascher-Svanum H, Zhu B, Faries D. et al . A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry. 2004; 3 11
- 6 Ascher-Svanum H, Zhu B, Faries D. et al . Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006; 6 8
- 7 Buxton M, Hanney S. How can payback from health services research be assessed?. J Health Serv Res Policy. 1996; 1 35-43
- 8 Citrome L. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. Int J Clin Pract. 2008; 62 837-840
- 9 Citrome L, Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother. 2008; 8 1079-1091
- 10 Citrome L, Stroup TS. Schizophrenia, clinical antipsychotic trials of intervention effectiveness (CATIE) and number needed to treat: How can CATIE inform clinicians?. Int J Clin Pract. 2006; 60 933-940
- 11 Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995; 310 452-454
- 12 de Haan L, van Amelsvoort T, Dingemans P. et al . Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders: a prospective five year follow-up. Pharmacopsychiatry. 2007; 40 264-268
- 13 Dossenbach M, Erol A, el Mahfoud Kessaci M. et al . Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry. 2004; 65 312-321
- 14 Dunayevich E, Ascher-Svanum H, Zhao F. et al . Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007; 68 1163-1171
- 15 Faries D, Ascher-Svanum H, Zhu B. et al . Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005; 5 26
- 16 Guyatt G, Rennie D.
Users’ Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice. Chicago, IL: AMA Press 2002: 111
- 17 Haro JM, Edgell ET, Jones PB. et al . The European Schizophrenia Outpatient Health Outcomes (SOHO) Study: rationale, methods and recruitment. Acta Psychiatr Scand. 2003; 107 222-232
- 18 Haro JM, Suarez D, Novick D. et al . Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007; 17 235-244
- 19 Karagianis J, Rosenbluth M, Tohen M. et al . Reviewing CATIE for clinicians: Balancing benefit and risk using evidenced-based medicine tools. Curr Med Res Opin. 2007; 23 2551-2557
- 20 Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry. 2006; 39 161-170
- 21 Lieberman JA, Stroup TS, McEvoy JP. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353 1209-1223
- 22 Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine. 2005; 3 21
- 23 Müller N. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry. 2004; 37 ((Suppl. 2)) S141-S147
- 24 Stauffer V, Karagianis J, Sutton V. et al . Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in randomized controlled trials comparing olanzapine to other antipsychotics for treatment of schizophrenia. Clin Schizophr Related Psychoses. 2008; 2 136-146
- 25 Suarez D, Haro JM, Novick D. et al . Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia. Pharmacopsychiatry. 2009; 42 135-140
- 26 Volovka J, Citrome L. All antipsychotics are equal, but some are more equal than others. J Clin Psychiatry. 2009; 70 429-430
Eli Lilly and Company
Lilly Research Centre
Erl Wood Manor
Phone: +44/(0)1276/483 832
Fax: +44/(0)1276/483 192